Kabra Drugs Limited

Equities

KABRADG

INE323K01017

Market Closed - Bombay S.E. Other stock markets 06:00:58 2024-07-08 am EDT			5-day change	1st Jan Change
8.3 ^INR	+4.93%		0.00%	+53.99%

Jul. 12	Kabra Drugs Limited Announces Change of Registered Office Address	CI
Jul. 05	Kabra Drugs Limited announced that it has received INR 56.905 million in funding	CI

Kabra Drugs Limited Announces Resignation of Mr. Kuldeep Kumar Ajmera as Independent Director

July 02, 2018 at 08:51 am EDT

Kabra Drugs Limited announced that Mr. Kuldeep Kumar Ajmera, Independent Director, has tendered his resignation from the Board of the company with effect from July 02, 2018 due to personal reasons.

Latest news about Kabra Drugs Limited

Kabra Drugs Limited Announces Change of Registered Office Address	Jul. 12	CI
Kabra Drugs Limited announced that it has received INR 56.905 million in funding	Jul. 04	CI
Kabra Drugs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	May. 30	CI
Kabra Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 14	CI
Kabra Drugs Limited announced that it expects to receive INR 56.905 million in funding	Jan. 22	CI
Kabra Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 13	CI
Kabra Drugs Limited Approves to Shift Registered Office	23-09-30	CI
Kabra Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14	CI
Kabra Drugs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-06-08	CI
Kabra Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
Kabra Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-14	CI
Kabra Drugs Limited Announces Resignation of Muralidharan R as Director	22-11-02	CI
Kabra Drugs Limited Announces Board Appointments	22-09-30	CI
Kabra Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-13	CI
Kabra Drugs Limited Announces Executive Changes	22-07-07	CI
Kabra Drugs Limited Announces Appointment of K.N Anand as Additional Director (Independent Director)	22-06-09	CI
Kabra Drugs Limited Announces Resignation of Churchil Durai M Jebastine as Director	22-05-30	CI
Kabra Drugs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	22-05-30	CI
Kabra Drugs Limited Reports Earnings Results for the Full Year Ended March 31, 2022	22-05-30	CI
Kabra Drugs Limited Announces Resignation of Pritam Paul as Secretary and Compliance Officer	22-04-18	CI
Kabra Drugs Limited Appoints Pritam Paul as Company Secretary and Compliance Officer	22-03-18	CI
Kabra Drugs Limited Announces the Resignation of Company Secretary and Compliance Officer Radhika Dammani	22-03-03	CI
Kabra Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-14	CI
Kabra Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-13	CI
Kabra Drugs Limited Approves to Shift Registered Office of the Company	21-09-30	CI

Chart Kabra Drugs Limited

Duration

Period

More charts

Company Profile

Sector

Calendar

2024-08-11 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data